SRTANasdaqServices-Health ServicesFiscal year ends December 31
Strata Critical Medical, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$4.54+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $391.41M
- P/E (TTM)
- 8.9
- Dividend yield
- –
Strata Critical Medical, Inc. revenue by segment
By business segment
| Revenue | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Medical Segment | $153.51M | $146.74M | $146.82M | $142.42M | $139.81M | $135.86M | $126.60M | – | 100.0% | +9.8% |
| Passenger | $100.84M | $104.75M | $101.88M | $99.39M | $98.57M | $95.56M | $98.58M | – | 65.7% | +2.3% |
| Operating income | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 21 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Medical Segment | – | – | – | – | – | – | -$1.39M | – | – |
| Passenger | – | – | – | – | – | – | -$33.50M | – | – |
By product or service
| Revenue | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Short Distance | – | – | – | – | – | – | – | $22.25M | – | – |
| MediMobility Organ Transport | – | – | – | – | – | – | – | $26.35M | – | – |
By region
| Revenue | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $226.26M | $221.82M | $218.75M | $208.71M | $204.06M | $198.05M | $190.74M | – | 147.4% | +10.9% |
| Other | $28.08M | $29.67M | $29.95M | $33.11M | $34.32M | $33.38M | $34.44M | – | 18.3% | -18.2% |
From the segment and revenue-disaggregation notes of Strata Critical Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.